Oliver Stanley

It’s not hard for pharma companies to appear villainous, but Mylan, the maker of the EpiPen, may be in a class by itself. Mylan has drawn the ire of patients, consumer groups and now Congress for raising the price of the device 400% since it acquired EpiPen in 2007. The implement, which delivers life-saving medicine for severe allergy sufferers, can now cost more than $300 per pen. It’s only sold in pairs and must be purchased every year because the drug, epinephrine, loses potency over time. Sales of EpiPen are now in excess of $1 billion annually...

Read More »